Novel cycloalkene‐fused thienopyrimidine analogues with enhanced phosphodiesterase 5
(PDE5) inhibitory properties are presented. The structure of the reported scaffold was …

This study aimed to assess the cavernous antioxidant effect of green tea (GT),
epigallocatechin‐3‐gallate (EGCG) with/without sildenafil citrate intake in aged diabetic rats …

Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly used treatment for
erectile dysfunction (ED). Since the launch of sildenafil, several drugs-including mirodenafil …

OBJECTIVE: To determine the efficacy of phosphodiesterase inhibitors for the treatment of
lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). DATA …

Introduction TPN729MA is a newly developed phosphodiesterase type 5 inhibitor (PDE5i)
for the treatment of erectile dysfunction, which offers potential for greater selectivity and …

Objective To study PDE 5 localisation by visualising the product of phosphodiesterase type
5 (PDE 5) inhibition, namely cGMP, to determine the site of action of inhibitors in the urinary …

Abstract Sildenafil, given shortly before 3, 4‐methylenedioxymethamphetamine (MDMA),
affords protection against 5‐hydroxytryptamine (5‐HT) depletions caused by this …

Endogenous glucocorticoids (GC) rapidly increase after acute exercise, and the
phosphodiesterase's type 5 inhibitor (PDE5i) tadalafil influences this physiological …

Introduction Insulin resistance features both endothelial dysfunction and increased oxidative
stress. Both disorders are targeted by a chronic treatment with sildenafil. However, the …